These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 31053248)

  • 1. Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy.
    Vija L; Dierickx L; Courbon F
    Ann Endocrinol (Paris); 2019 Jun; 80(3):166-171. PubMed ID: 31053248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
    Kulkarni HR; Baum RP
    PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radionuclide Therapy for Neuroendocrine Tumors.
    Cives M; Strosberg J
    Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRRT as neoadjuvant treatment in NET.
    Sowa-Staszczak A; Hubalewska-Dydejczyk A; Tomaszuk M
    Recent Results Cancer Res; 2013; 194():479-85. PubMed ID: 22918777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
    Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
    Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
    [No Abstract]   [Full Text] [Related]  

  • 7. Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.
    Di Franco M; Zanoni L; Fortunati E; Fanti S; Ambrosini V
    Curr Oncol Rep; 2024 May; 26(5):538-550. PubMed ID: 38581469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Theranostics for Well and Moderately Differentiated GEP-NEN].
    Hartrampf P; Werner R; Buck A
    Zentralbl Chir; 2022 Jun; 147(3):249-255. PubMed ID: 35705086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
    Harris PE; Zhernosekov K
    Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing precision: A predictive model for
    Akhavanallaf A; Joshi S; Mohan A; Worden FP; Krauss JC; Zaidi H; Frey K; Suresh K; Dewaraja YK; Wong KK
    Theranostics; 2024; 14(9):3708-3718. PubMed ID: 38948061
    [No Abstract]   [Full Text] [Related]  

  • 11. Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies.
    Mallak N; Yilmaz B; Meyer C; Winters C; Mench A; Jha AK; Prasad V; Mittra E
    Curr Probl Cancer; 2024 Oct; 52():101129. PubMed ID: 39232443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4D SPECT/CT acquisition for 3D dose calculation and dose planning in (177)Lu-peptide receptor radionuclide therapy: applications for clinical routine.
    Kairemo K; Kangasmäki A
    Recent Results Cancer Res; 2013; 194():537-50. PubMed ID: 22918781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Peptide receptor radionuclide therapy of neuroendocrine tumors].
    Arveschoug AK; Hjorthaug K; Rehling M; Højgaard L; Mortensen J; Oturai PS
    Ugeskr Laeger; 2009 Mar; 171(13):1073. PubMed ID: 19321068
    [No Abstract]   [Full Text] [Related]  

  • 16. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
    Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
    Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor radionuclide therapy in neuroendocrine tumors.
    Haider M; Das S; Al-Toubah T; Pelle E; El-Haddad G; Strosberg J
    Endocr Relat Cancer; 2021 Mar; 28(3):R81-R93. PubMed ID: 33608483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
    Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; de Herder WW; Krenning EP
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.
    Werner RA; Lapa C; Ilhan H; Higuchi T; Buck AK; Lehner S; Bartenstein P; Bengel F; Schatka I; Muegge DO; Papp L; Zsótér N; Große-Ophoff T; Essler M; Bundschuh RA
    Oncotarget; 2017 Jan; 8(4):7039-7049. PubMed ID: 27705948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.